The demonstration that NAC1 promotes tumor progression at least in part by forming molecular partnership with BCL6 should further our understanding on the intricate transcription network operated in ovarian cancer and provide a molecular foundation for designing new therapeutic strategy through targeting NAC1/BCL6 transcription complex. The gene discussed is NACC1; the disease is ovarian cancer.